Gilead Sciences News

Gilead Sciences is a multi-billion dollar biopharmaceutical company that develops medicines for a range of diseases. It is research based, so to stay up-to-date with that research, and to keep track of the performance of the company along with other issues, sign up for the Wiser Gilead Sciences news email. The drugs that Gilead Services produces treat conditions like HIV/AIDS, liver disease, cancer, cardiovascular and respiratory conditions. The company was founded in 1987 and is based in California. The president and chief executive officer is John Martin. It has about 7,000 employees and is ranked as one of the top drug companies in the US with sales in 2013 of over $11 billion. Its hepatitis-C drug, Sovaldi, is predicted to sell well, plus it is expected to continue its expansion through acquisitions. This is in addition to new drugs that the company is developing. The Gilead Sciences news email from Wiser is the best way to get the latest news and information on the company. It is free, so register today.

Recent Gilead Sciences News Coverage
 
Your Weekly Recommendations Saturday, September 23, 2017
 
Recommended for you
Biotech: The Big Payoff
Seeking Alpha • S.A. Marketplace
Cheaper hepatitis C treatment: It’s good, but…
Free Malaysia Today • Melissa Darlyne Chow
World Health Officials Describe Progress Against Tetanus, H.I.V. and Malaria
The New York Times • Donald G. Mcneil, Jr.
Oddly, Juno Therapeutics Is Jumping 11.3% Today
Fool.com: The Motley Fool • Todd Campbell
Your Daily Pharma Scoop: VanEck Vectors Biotech ETF, Esperion's Growth Potential, Pfizer's EU Approval
Seeking Alpha • Avisol Capital Partners
Why Is Cash-Rich Gilead Sciences, Inc. Borrowing $3 Billion?
Fool.com: The Motley Fool • Brian Orelli
3 Big Biotech Stocks to Buy This Fall
Fool.com: The Motley Fool • Keith Speights
Ask a Fool! We Answer Your Healthcare Questions on Trials, Patents, and Pharmacy Retailers
Fool.com: The Motley Fool • Todd Campbell
3 Biotech Stocks With Major Catalysts Incoming
Fool.com: The Motley Fool • Cory Renauer
Why Gilead Sciences Is Flying High With Kite
Forbes • Contributor Moneyshow
 
Recommended for You
Cancer, Finance
Biotech: The Big Payoff
Seeking AlphaS.A. Marketplace
Summary Dr. Tran BioSci joins the Roundtable to talk about opportunities with upside in biotech. He believes Gilead and other biotechs are likely to seek M&A partners to fulfill public demand for new drugs. Dr. Tran also thinks that orphan drug makers...
Share
Copyright, Gilead Sciences
Cheaper hepatitis C treatment: It’s good, but…
Free Malaysia TodayMelissa Darlyne Chow
Galen Centre for Health and Social Policy says the move by the ministry could also affect future innovations that depend on patent rights to protect their intellectual property. PETALING JAYA: A think tank has cautiously welcomed the health ministry’s move to make...
Share
Gilead Sciences, Health Care Industry
World Health Officials Describe Progress Against Tetanus, H.I.V. and Malaria
The New York TimesDonald G. Mcneil, Jr.
Infant and maternal tetanus was officially eliminated from the Americas this year, the Pan American Health Organization announced on Thursday. At onetime/one-time, the infection killed about 10,000 newborns annually in the Western Hemisphere; tetanus still kills about 35,000 infants around the world....
Share
Biotechnology, Gilead Sciences
Oddly, Juno Therapeutics Is Jumping 11.3% Today
Fool.com: The Motley FoolTodd Campbell
What happened Despite a 6.1 million-share follow-on public stock offering, shares of Juno Therapeutics (NASDAQ:JUNO) are rallying 11.3% higher at 3 p.m. EDT. So what Juno Therapeutics shares have been rallying since competitor Gilead Sciences (NASDAQ:GILD) acquired Kite Pharma, and competitor Novartis...
Share
Gilead Sciences, Health Finance
Your Daily Pharma Scoop: VanEck Vectors Biotech ETF, Esperion's Growth Potential, Pfizer's EU Approval
Seeking AlphaAvisol Capital Partners
Summary The VanEck Vectors Biotech ETF is discussed. Esperion's potential in the statin-intolerant anti-cholesterol market is discussed. Pfizer’s BAVENCIO (avelumab) is approved in Europe for the treatment of adult patients with metastatic Merkel cell carcinoma. Avisol Capital Partners, managed by Drs Udaya...
Share
Gilead Sciences, U.S. Congress
Why Is Cash-Rich Gilead Sciences, Inc. Borrowing $3 Billion?
Fool.com: The Motley FoolBrian Orelli
Last week, Gilead Sciences (NASDAQ:GILD) announced that it was borrowing $3 billion. That's billion with a "B." The company doesn't really need the money. It was sitting on $36.6 billion in cash, cash equivalents, and marketable securities at the end of the...
Share
Cancer, Gilead Sciences
3 Big Biotech Stocks to Buy This Fall
Fool.com: The Motley FoolKeith Speights
A change in season presents a good time to look for great stocks to buy. And one of the best places to look is in the biotech industry. Biotech stocks in general are trouncing the S&P 500 index so far in 2017....
Share
Gilead Sciences, Pharmaceuticals
Ask a Fool! We Answer Your Healthcare Questions on Trials, Patents, and Pharmacy Retailers
Fool.com: The Motley FoolTodd Campbell
If you've ever wondered why drugmakers run Phase I-II or II B clinical trials, how drugmakers like AbbVie (NYSE:ABBV) plan on keeping generic drugmakers at bay after their patents expire, or why pharmacy retailers like Walgreens Boots Alliance (NASDAQ:WBA) and CVS Health...
Share
Gilead Sciences, Medical Science & Research
3 Biotech Stocks With Major Catalysts Incoming
Fool.com: The Motley FoolCory Renauer
Axovant Sciences Ltd (NASDAQ:AXON) and PTC Therapeutics, Inc. (NASDAQ:PTCT) have drugs in late-stage development that could propel them to profitability over the next few years. Gilead Sciences, Inc. (NASDAQ:GILD) is already one of the most profitable companies on the planet, but a...
Share
Cancer, Finance
Why Gilead Sciences Is Flying High With Kite
ForbesContributor Moneyshow
Biotechnology has long been a favorite topic among newsletter advisors and Gilead Sciences GILD +0.30% has long been a favorite stock within the sector. Recent developments—including a large acquisition—have sparked increased interest in the stock, including commentary from these five MoneyShow.com contributors....
Share